Showing 6151-6160 of 7114 results for "".
- Novan: Top Line Phase 2 Data Positive for SB206 Gel for Molluscumhttps://practicaldermatology.com/news/novan-top-line-phase-2-data-positive-for-sb206-gel-for-molluscum/2457507/Top line results from Novan’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum are promising. Data for three full cohorts of four show that SB206 gel demonstrated a clear treatment effect on the complete clearance of
- Study Highlights Unique Characteristics of Melanoma Patients Who Use Tanning Bedshttps://practicaldermatology.com/news/study-highlights-unique-characteristics-of-melanoma-patients-who-use-tanning-beds/2457509/Younger individuals and females are more likely to use tanning beds, and as a result they tend to develop melanoma earlier, according to
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 201
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month/2457519/November is Hyperhidrosis Awareness Month. The International Hyperhidrosis Society (IHhS) wants the world to know that hyperhidrosis’ (Hh) uncontrollable, no-fault sweating can soak through clothing and water-damage electronics. This makes
- Ortho Dermatologics' Altreno Now Available in the UShttps://practicaldermatology.com/news/ortho-dermatologics-altreno-now-available-in-the-us/2457526/Ortho Dermatologics launched Altreno (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. Altreno Lotion is the first and only tretinoin available in a lotion for acne. Altreno Lotion has been shown to be effective and generally well-tolerated
- Skin Cancer Foundation: Champions for Change Gala Raises $600,000https://practicaldermatology.com/news/skin-cancer-foundation-champions-for-change-gala-raises-600000/2457527/The Skin Cancer Foundation’s 22nd annual Gala raised $600,000 to support the organization’s educational campaigns, community programs, and research initiatives. More than 400 guests attended the event, including Skin Cancer Foundation donors, industry and physician allies, celebrity s
- Researchers Identify Genes Involved in Skin Cancerhttps://practicaldermatology.com/news/researchers-identify-genes-involved-in-skin-cancer/2457528/Researchers at the Health Sciences department of the Universitat Jaume I (UJI) of Castellón, Spain, have identified the genes responsible for sun sensitivity and skin cancer vulnerability. The Skin Cancer Genetics and Human Pigmentation research group (Melanogén) has analysed the sk
- LA BioMed Team to Study Treatments for Antibiotic-Resistant Skin Infectionshttps://practicaldermatology.com/news/la-biomed-team-to-study-treatments-for-antibiotic-resistant-skin-infections/2457533/Investigators from LA BioMed have scored a $5.3M grant from the National Institutes of Health to study the effectiveness of treatments for antibiotic-resistant skin infections. The study,
- Actress Kristin Davis Partners with Coolsculpting for Denim Denial Programhttps://practicaldermatology.com/news/actress-kirstin-davis-partners-with-coolsculpting-for-denim-denial-program/2457532/"Sex and the City” star Kristin Davis is partnering with CoolSculpting for the new "Denim Denial" consumer program. Denim Denial recognizes that every woman has a pair of jeans on the top shelf of her closet or tucked away in a bottom drawer but is holding on to
- Almirall's Seysara Set to Shake Up US Acne Markethttps://practicaldermatology.com/news/almiralls-seysara-set-to-shake-up-us-acne-market/2457557/The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older is set to shake up the currently stagnant acne market due to its ease of adminis